Gout Therapeutics Landscape Reshaped by Strategic Collaborations and Licensing Deals | DelveInsight

The gout market is expected to experience significant growth across the 7MM, driven by increasing prevalence rates, an aging population, and advancements in personalized medicine. Key companies contributing to this growth include XORTX Therapeutics, Dyve Biosciences, Olatec Therapeutics, Arthrosi Therapeutics, AstraZeneca, RxOmeg Therapeutics, Sorrento Therapeutics, and Shanton Pharma, among others.
DelveInsight's latest report, "Gout - Market Insight, Epidemiology and Market Forecast - 2032 [https://www.delveinsight.com/report-store/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]," integrates robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments, offering valuable insights into the evolving treatment paradigm. The gout market within the 7MM-which includes the United States, EU5 (France, Germany, Italy, Spain, and the UK), and Japan-is projected to show notable growth with a respectable compound annual growth rate (CAGR) by 2032. This growth reflects the rising prevalence of gout, an aging demographic, and innovations in drug delivery systems and personalized medicine approaches.

Download the Gout Market report to understand which factors are driving the gout therapeutic market @ Gout Market Trends [https://www.delveinsight.com/sample-request/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The report offers an in-depth epidemiological analysis and forecasts through 2032. Gout affects approximately 3-4% of adults in the United States, with men being more commonly affected than women. Moreover, gout prevalence increases with age. it is lowest among individuals aged 20 to 39 years and highest among those aged 80 years or older.

The treatment landscape for gout has evolved markedly, with multiple effective options available for both acute flares and long-term management. Current first-line therapies for acute attacks include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids. For chronic management, xanthine oxidase inhibitors like allopurinol and febuxostat remain the cornerstone treatments. ZURAMPICIS (AstraZeneca), a urate transporter inhibitor, is also used to treat patients with gout, by removing excess uric acid near joints. It is recommended only as an adjuvant with either allopurinol or febuxostat when these medications are not sufficient.

Discover evolving trends in the gout patient pool forecasts @ Gout Epidemiology Analysis [https://www.delveinsight.com/sample-request/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

DelveInsight's analysis indicates that several companies are launching clinical trials to explore new gout treatment options or enhance existing ones. The clinical development pipeline for gout includes drugs such as DYV700 (Dyve), AR882 (Arthrosi Therapeutics), DYV700 (Dyve Biosciences), Dapansutrile (Olatec Therapeutics) and XRx-026 (XORTX Therapeutics), among others.

In March 2025, XORTX Therapeutics (NASDAQ: XRTX) announced a Type B meeting with the FDA scheduled for late April 2025 to discuss its proprietary formulation, XRx-026, for gout treatment. Towards the close of March 2025, Shanton Pharma reported positive top-line results from a Phase IIb clinical trial of its investigational gout therapy, SAP-001, targeting patients who are unresponsive to existing treatments. These developments underscore the momentum in the gout treatment landscape.

Furthermore, in January 2025, Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), amended its license agreement with RxOmeg Therapeutics LLC (ROMEG) to obtain the exclusive rights to market and distribute GLOPERBA worldwide. Previously, in June 2022, Scilex had received marketing and distribution rights only for the US. Gloperba is the first liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Unlock which gout emerging drug is expected to capture the largest market share in 7MM by 2032. Visit the Gout Drug Insights [https://www.delveinsight.com/sample-request/gout-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

The evolving landscape of gout treatment reflects significant progress in addressing unmet medical needs through innovative therapies. Emerging biologics, advanced drug delivery systems, and personalized medicine approaches are poised to redefine treatment strategies for both acute flares and chronic disease management. As these therapies gain regulatory approval and enter the market, they hold promise for improved patient outcomes and enhanced quality of life.

Table of Contents

1. Report Introduction

2. Executive Summary of Gout Pain

3. Gout Pain Market Share at a glance

4. Executive Summary of Gout Pain

5. Key Events

6. Gout Epidemiology and Market Methodology

7. Gout Background and Overview

8. Gout Pain Epidemiology and Patient Population

9. Country-Wise: Epidemiology of Gout Pain

10. Patient Journey

11. Gout Marketed Therapies

12. Gout Emerging Therapeutics

13. Market Size of Gout Pain

14. Gout Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Reimbursement and Market Access

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Gout Pipeline Insight [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Gout Pipeline Insight provides comprehensive insights about the gout pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the gout companies, including Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, and Shenyang Sunshine Pharmaceutical, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gout-therapeutics-landscape-reshaped-by-strategic-collaborations-and-licensing-deals-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.